MeerMinder Bedrijfsinformatie

reMYND | Driving the development of disease-modifying treatments Jump to navigation About us Events News Jobs Contact Search form Search reMYND drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes and other protein misfolding disorders …through two independently managed business units: Contract Research The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND’s proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. Drug discovery The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (α-synuclein), and Diabetes. Home Contract research Drug discovery Events BioJapan 2014 15-10-2014 to 17-10-2014 SfN, Washington DC 15-11-2014 to 19-11-2014 View all events Latest news LTP measurements available through reMYND reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models Tulips for Parkinson’s Contract research APP-models TAU-models APPxTAU-models Drug discovery Disease areas Products in pipeline About us News Jobs Contact Partners CRO News Flashes